Diabetes mellitus is a common disease in cats. Most diabetic cats depend on insulin therapy to survive but traditional insulin formulations are associated with adverse effects and poor compliance. Novel insulin analogs and incretin-based therapies are more effective and have fewer side effects than traditional therapies. We studied some of these novel therapies in healthy cats. We used the isoglycemic clamp method to compare the pharmacodynamics of the synthetic insulin analogs, insulin detemir and insulin glargine. An analog-sensitive insulin ELISA was used at the same time to measure exogenous insulin concentrations. We also used the isoglycemic clamp method to study the pharmacodynamics of the GLP-1 mimetic, exenatide. An exenatide-specific ELISA was used for evaluation of exenatide pharmacokinetics. Finally, we studied the incretin effect in cats and compared the effect of glucose, lipids or amino acids on secretion of the incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). The isoglycemic clamp method was used to compare the effects of the 3 treatments on insulin secretion. We found that insulin detemir and insulin glargine have simila
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.